(NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation ...
A Science Immunology Review explains how memory B cells acquire diverse molecular, epigenetic, and tissue-specific programs ...
A new HIV vaccine developed by La Jolla Institute for Immunology (LJI), Scripps Research scientists and IAVI has the potential to protect humans from developing HIV infection and AIDS. This HIV ...
ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth ...
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million ...
Learn more about whether Ionis Pharmaceuticals, Inc. or Nurix Therapeutics, Inc. is a better investment based on AAII's A+ ...
5d
Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade)
Fate Therapeutics pivots to autoimmune CAR T-cell therapies, with FT819 advancing toward a registrational lupus nephritis ...
The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1; EVX-V1 is a next-gene ...
According to the latest market analysis by Future Market Insights, the global B-Cell Depletion Therapy Market is projected to ...
Vor Biopharma pivots to telitacicept for autoimmune diseases, backed by $491M cash to 2029. Click here to read an analysis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results